The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11149 malaria professionals are enjoying the free benefits of MalariaWorld today

Primaquine

Plasmodium vivax infection with exflagellated microgametes in peripheral blood smears

March 23, 2021 - 14:34 -- Open Access
Author(s): 
Li THS, Lee ACH, Wong WS, Yip YL
Reference: 
Int J Infect Dis. 2021 Mar 18:S1201-9712(21)00267-8

A 42-year-old man with travel history to Qatar and India was admitted for feverish sensation, headache and epigastric discomfort. Peripheral blood smears showed intraerythrocytic parasites compatible with Plasmodium vivax [Fig. 1 (a) and (b)].

Primaquine plus clindamycin as a promising salvage therapy for Pneumocystis jirovecii pneumonia: A retrospective analysis in Japanese patients

March 17, 2021 - 09:12 -- Open Access
Author(s): 
Koga M, Suganuma A, Kikuchi T, Yoshimura Y, Shoji K, Kobayashi I, Takezaki S, Kato Y, Kimura M, Maruyama H
Reference: 
J Infect Chemother. 2021 Mar 13:S1341-321X(21)00070-2

Treatment of intractable Pneumocystis jirovecii pneumonia (PCP) patients with primaquine (PQ) in combination with clindamycin (CLDM) was conducted by the Research Group on Chemotherapy of Tropical Diseases (RG-CTD), as a kind of compassionate use. Primaquine was not nationally licensed at the time but imported by RG-CTD for the use in a clinical research to investigate safety and efficacy in malaria treatment.

NOT Open Access | A Novel Hybrid of Chloroquine and Primaquine Linked by Gold(I): Multitarget and Multiphase Antiplasmodial Agent

February 25, 2021 - 08:21 -- NOT Open Access
Author(s): 
de Souza Pereira C, Costa Quadros H, Navarro M, et al.
Reference: 
ChemMedChem. 2021 Feb 17;16(4):662-678

Plasmodium parasites kill 435 000 people around the world every year due to unavailable vaccines, a limited arsenal of antimalarial drugs, delayed treatment, and the reduced clinical effectiveness of current practices caused by drug resistance. Therefore, there is an urgent need to discover and develop new antiplasmodial candidates. In this work, we present a novel strategy to develop a multitarget metallic hybrid antimalarial agent with possible dual efficacy in both sexual and asexual erythrocytic stages.

Diagnostic Practices and Treatment for P. vivax in the InterEthnic Therapeutic Encounter of South-Central Vietnam: A Mixed-Methods Study

January 6, 2021 - 13:13 -- Open Access
Author(s): 
Nguyen TT, Nguyen XX, Gryseels C, et al.
Reference: 
Pathogens. 2020 Dec 31;10(1):E26

Malaria elimination in the Greater Mekong Sub-Region is challenged by a rising proportion of malaria attributable to P. vivax. Primaquine (PQ) is effective in eliminating the parasite's dormant liver stages and can prevent relapsing infections, but it induces severe haemolysis in patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, highlighting the importance of testing enzyme activity prior to treatment.

NOT Open Access | Antimalarial and anti-inflammatory activities of new chloroquine and primaquine hybrids: Targeting the blockade of malaria parasite transmission

December 16, 2020 - 10:03 -- NOT Open Access
Author(s): 
Boechat N, Carvalho RCC, Ferreira MLG, Coutinho JP, Sa PM, Seito LN, Rosas EC, Krettli AU, Bastos MM, Pinheiro LCS
Reference: 
Bioorg Med Chem. 2020 Dec 15;28(24):115832

Malaria is a disease that requires new drugs not only to fight Plasmodium but also to reduce symptoms of infection such as fever and inflammation. A series of 21 hybrid compounds were designed from chloroquine (CQ) and primaquine (PQ) linked to the pharmacophoric group present in phenylacetic anti-inflammatory drugs. These compounds were designed to have dual activity: namely, to be capable of killing Plasmodium and still act on the inflammatory process caused by malaria infection.

NOT Open Access | Ligand Decorated Primaquine loaded Nanocarriers for Liver Targeting for Triggered Antimalarial Activity

December 3, 2020 - 12:56 -- NOT Open Access
Author(s): 
Paramjot Mehan, Ashish Garg, Kumar Ajay, Neeraj Mishra
Reference: 
Curr Mol Pharmacol. 2020 Nov 25

The aim of the current research to formulate a nano delivery system for effective delivery of primaquine for liver targeting to achieve the potential antimalarial activity. An objective of current development is to formulate a lactobionic acid conjugated polyphosphazene based nanodelivery of primaquine for liver targeting to distinguish antimalarial activity.

Evaluation of a single screen and treat strategy to detect asymptomatic malaria among pregnant women from selected health facilities in Lindi region, Tanzania

December 2, 2020 - 09:45 -- Open Access
Author(s): 
Chonge Kitojo, Frank Chacky, Emmanuel S. Kigadye, Joseph P. Mugasa, Abdallah Lusasi, Ally Mohamed, Patrick Walker, Erik J. Reaves, Julie R. Gutman & Deus S. Ishengoma
Reference: 
Malar J 19, 438 (2020)

In areas of high transmission, malaria in pregnancy (MiP) primarily causes asymptomatic infections; these infections nonetheless increase the risk of adverse maternal and fetal outcomes. In 2014, Tanzania initiated a single screening and treatment (SST) strategy for all pregnant women at their first antenatal care (ANC) visit using malaria rapid diagnostic tests (RDT) for surveillance purposes. However, there is paucity of data on the effectiveness of SST in the prevention of MiP. The objective of this study was to estimate the number of asymptomatic infections among pregnant women detected by SST, which would have been missed in the absence of the policy.

A small window into the status of malaria in North Korea: estimation of imported malaria incidence of the visitors

November 25, 2020 - 12:13 -- Open Access
Author(s): 
Sung J, Cheong HK, Lim AY, Kim JH
Reference: 
Epidemiol Health. 2020 Nov 21:e2020068

This study aimed to hypothesize on the trend in malaria incidence in North Korea using malaria incidence among South Korean visitors to North Korea.

The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia

November 12, 2020 - 15:44 -- Open Access
Author(s): 
Thriemer K, Poespoprodjo JR, Kenangalem E, Douglas NM, Sugiarto P, Anstey NM, Simpson JA, Price RN
Reference: 
PLoS Negl Trop Dis. 2020 Nov 11;14(11):e0008838

The widespread use of primaquine (PQ) radical cure for P. vivax, is constrained by concerns over its safety. We used routinely collected patient data to compare the overall morbidity and mortality in patients treated with and without PQ without prior testing of Glucose-6-Phosphate-Dehydrogenase (G6PD) deficiency in Papua, Indonesia, where there is a low prevalence of G6PD deficiency. Records were collated from patients older than 1 year, with P. vivax infection, who were treated with an artemisinin combination therapy (ACT).

Absence of gender influence on the pharmacokinetics of chloroquine combined with primaquine in malaria vivax patients

November 7, 2020 - 12:25 -- Open Access
Author(s): 
Vieira MVDF, Mello AGCN, Sena LWP, Vieira JLF
Reference: 
Rev Inst Med Trop Sao Paulo. 2020 Oct 30;62:e83

Chloroquine is the first-line therapy against the asexual stages of Plasmodium vivax . There is a high variation of chloroquine plasma levels after therapeutic doses, which can lead to inadequate exposure to the drug. The gender influence was low regarding the disposition of the drug, which is relevant as there are significant physiological variations between male and female patients.

Pages

Subscribe to RSS - Primaquine